SUBSCRIBE
SUBSCRIBE
News   Drug Development

Johnson & Johnson Provides Added Doxil Supply for Clinical Studies

August 3, 2012 | 
1 min read
Johnson & Johnson (JNJ) will provide additional supply of its cancer drug Doxil for use in clinical trials, including one testing whether the combination of an experimental Endocyte Inc. (ECYT) drug with Doxil improves treatment of ovarian cancer.
Clinical research Postmarket research
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Business people and concepts vector art exit
Business
Takeda’s long-term R&D head announces exit after major pipeline reorganization
September 10, 2026
 · 
2 min read
 · 
Gabrielle Masson
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
FDA
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
September 10, 2026
 · 
3 min read
 · 
Heather McKenzie
Vector cartoon illustration of a business team standing at a crossroad with multiple arrows, discussing and choosing the right path toward success and future opportunities.
Drug pricing
Drugmakers cherry pick launch regions as MFN creates ‘policy environment like an earthquake’
September 10, 2026
 · 
4 min read
 · 
Annalee Armstrong
Composite collage picture image of man slide down arrow recession statistics data weird freak bizarre unusual fantasy billboard comics.
Bladder cancer
Tyra shares slip as bladder cancer responses fall short of investor expectations
September 10, 2026
 · 
2 min read
 · 
Tristan Manalac